Cancer is invariably emerging as one of the most deadly diseases in the world. Various researches are still on in order to find a sure shot treatment for all kinds of cancer. One of the commonest cancers of the reproductive organ in women, ovarian cancer kills many women due to its late diagnosis.
Though surgery, chemotherapy and radiation treatment are the standard methods of treating ovarian cancer, it may not be effective on all patients.
Going by the statistics that more than half of the women diagnosed with ovarian cancer die and one out of every 57 women contract the disease, a lot of research needs to be done before we can find a definite treatment for ovarian cancer. Here are some optional experimental treatment methods for ovarian cancer.
Experimental Medicine For Ovarian Cancer
Ovarian cancer vaccine is one of the newest additions for treating ovarian cancer. Known to be very effective, it is still too early to predict its efficacy as there are not enough researches to prove its worth. But many women who have undergone clinical trials have shown encouraging results.
The vaccine however helps patients with ovarian cancer of the epithelial cells which is the commonest form of ovarian cancer. Administration of this vaccine helps in increasing the levels of blood in CD8 and CD4 T cells which in turn results in increase immune function responses that help in the prevention of cancer cells from recurring.
Trabectedin is a cancer drug that is used for the treatment of other types of cancers. Recent research on this medicine has discovered that Trabectedin can help in preventing and treating cases of recurrent ovarian cancer. This however is still in the experimental stage and hence can be tried along with your normal treatment methods like chemotherapy and radiation treatment.
When used in combination with chemotherapy, Trabectedin is known to have increased the life expectancy of patients by about 7-9 months as compared to patients who took only chemotherapy.
Intraperitoneal chemotherapy is a more advanced and concentrated form of chemotherapy where the drug is injected directly into the abdominal region for greater effect. This type of chemotherapy has more side effects and is not generally done by doctors even though the survival rate increases with this treatment.
However, a combination of intraperitoneal and intravenous chemotherapy is done in some cases to optimise the effect of chemotherapy. Patients who received combination chemotherapy have survived up to 1 ½ years more than others who received only intravenous chemotherapy.
According to a Japanese research, a clinical trial was conducted where in the normal cycle of chemotherapy was administered to a few ovarian cancer patients wherein carboplatin and paclitaxel was given in six cycles every three weeks. Few others were given a modified cycle of six chemotherapy cycles of carboplatin every 3 weeks and one dose of paclitaxel once every week.
The comparison showed that patients who underwent the modified chemotherapy treatment had up to 25% less chances of death than the others who received the standard dose of chemotherapy treatment.